FDA Hits Fusion IV for Incomplete Labeling, Environmental Monitoring

Drug Industry Daily
A A
The FDA cited Fusion IV Pharmaceuticals for incomplete labels and failing to properly monitor environmental conditions.

To View This Article:

Login

Subscribe To Drug Industry Daily